Oxford Genetics secures £1.61m grant to establish next-generation bioproduction technologies
The project aims to create a step-change in the capabilities of current bioproduction methods, meeting unmet needs in the field of viral vector production.
Oxford Genetics has secured a £1.61 million grant from Innovate UK. The funding will support a new research project exploring computational and synthetic biology approaches for optimised mammalian bioproduction.
In collaboration with leading researchers at the University of Oxford, Oxford Genetics will take a systematic view to enhancing bioproduction and synthetic biology. The project will explore the use of complex statistical methods to engineer robust and predictable synthetic genetic constructs for expression of multi-component systems, as exemplified by bispecific proteins and viral vectors for gene therapy applications.
Research will also be conducted into the optimisation of the cellular environment to better support associated biosynthetic processes, and include proof-of-concept process development for scale-up.
Commenting on the announcement, Ryan Cawood, CEO at Oxford Genetics, said: “This grant means we can expedite research across our platform technologies, while demonstrating their full capabilities for enabling synthetic biology and bioproduction.
“The UK has world-leading expertise in cell and gene therapy in terms of both the science underpinning discovery and the ability to progress therapies to clinical testing. Developments in this area in particular highlight the need for robust, predicable and scalable bioproduction and cellular engineering technologies.”
With the global cell and gene therapy market estimated to be worth £9 to £14 billion per year by 2025, advanced therapies, including cell and gene therapies, represent a priority area for the UK’s life sciences sector.
Oxford Genetics’ latest initiative builds on previous research programs around the development of DNA design algorithms, automation platforms and viral packaging systems. The project aims to create a step-change in the capabilities of current bioproduction methods, meeting unmet needs in the field of viral vector production.
Len Seymour, Professor of Gene Therapy at the University of Oxford, said: “I look forward to building on the success of our past collaborations with Oxford Genetics. Together we hope to enable significant advancements to the field of viral delivery systems.”
Zubin Siganporia, Visiting Fellow in Mathematics at the University of Oxford and Managing Director at QED Analytics, commented: “The application of complex statistical approaches to improve the understanding of biological processes, and enable predictive engineering of biological systems, is gathering significant pace. We are excited to be working with the team at Oxford Genetics to explore these innovative technologies.”
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.